Introduction The process of drug development is fraught with uncertainty, requiring companies to make high-stakes decisions across a landscape defined by scientific complexity, long timelines, regulatory unpredictability, and commercial risk. Despite advances in biomedical science and access to vast datasets, many critical development and portfolio decisions continue to rely on fragmented...

New company delivers AI-powered portfolio modeling platform to support capital allocation, risk management and innovation in drug development Cambridge, MA--May 29, 2025--QLS Technologies LLC launched today as a spinout from QLS Advisors LLC, with a mission to apply financial engineering to foster innovation in the life sciences. As biomedicine has grown more complex, financing strategy has...